Benefits
The only clinically proven naturally sourced health product to use Ze 450 in Canada.
-
Reduce the frequency and severity of menopausal symptoms in all stages of menopause, from premenopause, perimenopause and postmenopause.
-
Offers effective relief of multiple symptoms related to menopause, from mild to severe, including hot flashes, night sweats, fatigue, irritability, nervousness, sleeplessness, mild joint pains, and headaches.
-
Available without prescription
-
Hormone and drug-free
-
Clinically proven
-
Relief as early as 6 weeks
-
Generally safe and well-tolerated
Overview
Clinically proven solution
Offering
multi-symptom relief
Cimidona® is the only evidence-based natural health product in Canada to use the exclusive extract of Actaea racemosa (Black cohosh), called Ze 450. Effective against various menopausal symptoms, this over-the-counter solution offers relief in as early as 6 weeks.
The roots of the plant are used to produce the extract.
Multi-symptom relief
Effective relief from hot flashes, night sweats, fatigue, irritability, nervousness, sleeplessness, mild joint pains & headaches associated with menopause
Clinically proven
Efficacy and safety of Ze 450 proven by one randomised, placebo-controlled, well-designed trial and multiple observational studies
Naturally sourced solution
Exclusive natural extract of Actaea racemosa, Ze 450, Cimidona® is hormone free
Efficacy
How does Cimidona® work?
Cimidona® contains an exclusive extract from the plant Actaea racemosa (Black Cohosh), Ze 450
All about Ze 450
What makes this specific Ze 450 extract unique is that it is produced using a thorough process with strict control at each step of growing, cultivating, extracting and producing.
This leads to:
High Quality & Consistent Potency with a calculated balance of active components
Quality Control, ensures reliability in every batch
Results, as supported in clinical trials
The meticulous process sets Cimidona® apart for its quality and reliability.
Usage & Dosage
Recommended Dosage - Adults 18 years and older. One tablet once a day. Use for a minimum of 6 weeks to see beneficial effects.
Medicinal Ingredients (per tablet) - Ze 450 (Actaea racemosa / Black Cohosh dry extract) 13 mg
Non-medicinal Ingredients - Colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone.
Storage - Room temperature
Cautions & Warnings
Consult a doctor if
symptoms persist or worsen, and
you have a liver disorder or develop symptoms of liver troubles.
Do not use if you are pregnant or breastfeeding.
Get inspired to Break the cycle.
Clinical Studies on Ze 450
Specific extract of Actaea racemosa (Black cohosh)
-
Safely used since 2005
-
#1 selling treatment for relief of menopausal symptoms in Switzerland*
*IQVIA, national sales data Switzerland, sell-in (pharmacy drugstore, self-dispensing Doctors, turnover (ex-factory), in CHF, MAT June 2023.
Ze 450 has demonstrated proven clinical efficacy over the years.
Schellenberg R et al., 20121
180 women with menopausal complaints (above 40 years) studied over 12 weeks.
Key points
-
Significant reduction in severity of menopausal symptoms (vasomotor, psychological, and somatic) compared to placebo
-
Significant improvement in self assessed quality of life (QoL)
-
Ze 450 shown to be an effective and well-tolerated nonhormonal treatment option for menopausal symptom relief
Drewe et al., 20132
442 women with menopausal complaints followed for 12 weeks.
Key points
-
Significant reduction in the severity of menopausal symptoms after 3 months of treatment
-
Continued treatment improved menopausal symptoms with significant relief at 9 months
-
Ze 450 was very well-tolerated
The data captured above comes from observational studies. It should be interpreted cautiously as it is not a randomised controlled trial.Friederichsen et al., 20193
174 women with menopausal complaints over 40 years studied retrospectively.
Only 13 mg is available in Canada.
Key points
-
Significant improvements in menopausal symptoms in both groups
-
No changes in body weight were observed during the study period in either group
The data captured above comes from observational studies. It should be interpreted cautiously as it is not a randomised controlled trial.1. Randomised, double-blind, placebo-controlled study - compared to placebo (p < 0.0001)
Patients took the Ze 450 extract (13 mg) or placebo daily for a period of 12 weeks.The primary outcome was the difference in menopausal symptoms experienced (vasomotor, psychological and somatic) observed between Week 12 and the established baseline.
2. Observational study - (p < 0.001)
Patients took 1 Cimidona® 13 mg tablet daily for a period 3 months while others continued on the 13 mg dose for another 6 months. The outcomes measured the total menopausal severity scores and its sub-items at 3 months and at 9 months compared to the baseline.
3. Monocentric retrospective cohort study
Women experiencing menopausal symptoms were treated with either Ze 450 6.5 mg (22% of women) or 13 mg (78% of women) or any menopausal hormone therapy (MHT) and had at least one follow-up consultation during the 12-month follow-up period. The outcomes assessed retrospectively were the comparison of Ze 450 (regardless of the dose) and MHT on metabolic parameters and body weight.
Women first consultation between 2009 and 2016 were screened. Included in the final analysis were 2 groups: women treated with either MHT or Cimidona® and having at least one follow-up consultation. Metabolic serum parameters (lipids, glucose, insulin, and HOMA-IR), body weight, and menopausal symptoms [Menopause Rating Scale (MRS)-II] were the main outcome measures. Statistical analysis by uni- and multivariable linear mixed-effects regression models assuming a linear effect of time.
